Viatris Inc.’s executive chairman Robert Coury will transition from his current position to chairman emeritus and senior strategic adviser to the board and management, the company announced Monday.
The move will follow the pharmaceutical company’s annual shareholder meeting in mid-December.
Coury will continue to serve in this new non-employee capacity until the end of 2025 when the term of his contract would have otherwise expired, the company said, to help limit potential disruptions.
Coury was the executive chairman of Mylan N.V. before it transitioned into privately held Viatris — which was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. The company employs about 38,000 globally and has offices in Cecil and Southpointe.
Viatris will select an independent board chair in the coming months.
A new CEO, Scott A. Smith, took the helm, effective April 1.
“With Viatris’ powerful foundation now securely in place, with Scott A. Smith at the helm as our new CEO, and with the clear and defined path that we established for growth going forward, I have never been more confident in the future of our company, our employees and all of our stakeholders than I am today,” Coury said in a statement.
